BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 9664152)

  • 1. Prognostic value of biomarkers in malignant melanoma.
    Hernberg M; Turunen JP; von Boguslawsky K; Muhonen T; Pyrhönen S
    Melanoma Res; 1998 Jun; 8(3):283-91. PubMed ID: 9664152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of CD40, CD44, bcl-2 antigens and rate of cell proliferation on fine needle aspirates from metastatic melanoma.
    Sviatoha V; Rundgren A; Tani E; Hansson J; Kleina R; Skoog L
    Cytopathology; 2002 Feb; 13(1):11-21. PubMed ID: 11985564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemically detectable bcl-2 expression in metastatic melanoma: association with survival and treatment response.
    Vlaykova T; Talve L; Hahka-Kemppinen M; Hernberg M; Muhonen T; Collan Y; Pyrhönen S
    Oncology; 2002; 62(3):259-68. PubMed ID: 12065874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 and mdm-2 expression in malignant melanoma: an immunocytochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumors.
    Gelsleichter L; Gown AM; Zarbo RJ; Wang E; Coltrera MD
    Mod Pathol; 1995 Jun; 8(5):530-5. PubMed ID: 7675773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of cell-cycle-regulated proteins pRb2/p130, p107, p27(kip1), p53, mdm-2, and Ki-67 (MIB-1) in prostatic gland adenocarcinoma.
    Claudio PP; Zamparelli A; Garcia FU; Claudio L; Ammirati G; Farina A; Bovicelli A; Russo G; Giordano GG; McGinnis DE; Giordano A; Cardi G
    Clin Cancer Res; 2002 Jun; 8(6):1808-15. PubMed ID: 12060621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ki-67, Bcl-2 and p53 expression in primary and metastatic melanoma.
    Ilmonen S; Hernberg M; Pyrhönen S; Tarkkanen J; Asko-Seljavaara S
    Melanoma Res; 2005 Oct; 15(5):375-81. PubMed ID: 16179864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer.
    Moul JW; Bettencourt MC; Sesterhenn IA; Mostofi FK; McLeod DG; Srivastava S; Bauer JJ
    Surgery; 1996 Aug; 120(2):159-66; discussion 166-7. PubMed ID: 8751578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apoptosis and expression of bcl-2 protein are inverse factors influencing tumour cell turnover in primary carcinoid tumours of the lung.
    Zirbes TK; Lorenzen J; Baldus SE; Moenig SP; Wolters U; Ottlik A; Thiele J; Hölscher AH; Dienes HP
    Histopathology; 1998 Aug; 33(2):123-8. PubMed ID: 9762544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrin chains beta1 and alphav as prognostic factors in human metastatic melanoma.
    Nikkola J; Vihinen P; Vlaykova T; Hahka-Kemppinen M; Heino J; Pyrhönen S
    Melanoma Res; 2004 Feb; 14(1):29-37. PubMed ID: 15091191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical analysis of the S100A1, S100B, CD44 and Bcl-2 antigens and the rate of cell proliferation assessed by Ki-67 antibody in benign and malignant melanocytic tumours.
    Sviatoha V; Tani E; Kleina R; Sperga M; Skoog L
    Melanoma Res; 2010 Apr; 20(2):118-25. PubMed ID: 20042890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of cyclin D1, p53, and MDM2 protein expression in uveal melanoma.
    Coupland SE; Anastassiou G; Stang A; Schilling H; Anagnostopoulos I; Bornfeld N; Stein H
    J Pathol; 2000 Jun; 191(2):120-6. PubMed ID: 10861569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 and related proteins in epithelial ovarian cancer.
    Sengupta PS; McGown AT; Bajaj V; Blackhall F; Swindell R; Bromley M; Shanks JH; Ward T; Buckley CH; Reynolds K; Slade RJ; Jayson GC
    Eur J Cancer; 2000 Dec; 36(18):2317-28. PubMed ID: 11094305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53-protein and Ki-67-antigen expression are both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin.
    Vogt T; Zipperer KH; Vogt A; Hölzel D; Landthaler M; Stolz W
    Histopathology; 1997 Jan; 30(1):57-63. PubMed ID: 9023558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates.
    Nakopoulou L; Vourlakou C; Zervas A; Tzonou A; Gakiopoulou H; Dimopoulos MA
    Hum Pathol; 1998 Feb; 29(2):146-54. PubMed ID: 9490274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
    Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
    Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical analysis of Bcl-2, nuclear S100A4, MITF and Ki67 for risk stratification of early-stage melanoma - A combined IHC score for melanoma risk stratification.
    Jurmeister P; Bockmayr M; Treese C; Stein U; Lenze D; Jöhrens K; Friedling F; Dietel M; Klauschen F; Marsch W; Fiedler E; von Laffert M
    J Dtsch Dermatol Ges; 2019 Aug; 17(8):800-808. PubMed ID: 31437373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients.
    Gradilone A; Gazzaniga P; Ribuffo D; Scarpa S; Cigna E; Vasaturo F; Bottoni U; Innocenzi D; Calvieri S; Scuderi N; Frati L; Aglianò AM
    J Clin Oncol; 2003 Jan; 21(2):306-12. PubMed ID: 12525523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of p53, MDM2 and bcl-2 expression in transitional cell carcinoma of the bladder.
    Uchida T; Minei S; Gao JP; Wang C; Satoh T; Baba S
    Oncol Rep; 2002; 9(2):253-9. PubMed ID: 11836589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary melanoma of the skin and cutaneous melanomatous metastases: comparative histologic features and immunophenotypes.
    Guerriere-Kovach PM; Hunt EL; Patterson JW; Glembocki DJ; English JC; Wick MR
    Am J Clin Pathol; 2004 Jul; 122(1):70-7. PubMed ID: 15272532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer.
    Baekelandt M; Kristensen GB; Nesland JM; Tropé CG; Holm R
    J Clin Oncol; 1999 Jul; 17(7):2061. PubMed ID: 10561259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.